Triple-negative breast cancer (TNBC) represents 10-20% of breast cancers and is characterized by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression, leaving cytotoxic chemotherapy as the main systemic treatment. This evidence concerns the gene ERBB2 and breast cancer.